Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Pharmaceuticals
Cytos licenses vaccine to Novartis
April 30, 2007
| A version of this story appeared in
Volume 85, Issue 18
Cytos Biotechnology has licensed CYT002-NicQb, a therapeutic vaccine in Phase II development for the treatment of nicotine addiction, to fellow Swiss firm Novartis. Cytos will get close to $30 million up front from Novartis and could receive almost $500 million in various milestone payments. According to Cytos, vaccination with CYT002-NicQb has been shown to induce nicotine-specific antibodies that bind nicotine in the bloodstream.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter